The immunology of psychiatric disorders;Psychische erkrankungen und immunsystem

PPmP Psychotherapie Psychosomatik Medizinische Psychologie

Volumn 55, Issue 1, 2005, Pages 36-48

  Arolt, Volker ^a   Rothermundt, Matthias ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Anxiety; Cytokine; Depression; Immunology; Posttraumatic stress disorder; Schizophrenia

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ANXIETY DISORDER; CYTOKINE PRODUCTION; DEPRESSION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; SCHIZOPHRENIA; STRESS DISORDERS, POST-TRAUMATIC;

EID: 13144250169     PISSN: 09372032     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-834580     Document Type: Review

References (146)

1. Arolt V, Rothermundt M, Peters M, Leonard B. Immunological research in clinical psychiatry: report on the consensus debate during the 7th Expert Meeting on Psychiatry and Immunology. Mol Psychiatry 2002; 7: 822-826
2. Bartrop RW, Lazarus L, Luckhurst E, Kiloh LG. Depressed lymphocyte function after bereavement. Lancet 1977; 83: 834-836
3. Marazitti D, Ambrogi F, Vanacore R et al. Immune cell imbalance in major depressive and panic disorders. Neuropsychobiol 1992; 26: 23-26
4. Müller N, Hofschuster E, Ackenheil M et al. Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Progr Neuropsychopharmacol Biol Psychiatry 1993; 17: 713-730
5. Legros S, Mendlewicz J, Wybran J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 1985; 235: 9-11
6. Seidel A, Arolt V, Hunstiger M et al. Cytokine production and serum proteins in depression. Scand J Immunol 1995; 41: 534-538
7. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res 1997; 43: 529-534
8. Joyce PR, Hawes CR, Mulder RT et al. Elevated levels of acute phase proteins in major depression. Biol Psychiatry 1992; 32: 1035-1041
9. Maes M, Scharpe S, Bosmans E et al. Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness. Progr Neuropsychopharmacol Biol Psychiatry 1992 a; 16: 501-515
10. Maes M, Delanghe J, Ranjan R et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997 c; 66: 1-11
11. Song C, Dinan T, Leonard BE. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 1994; 30: 283-288
12. Maes M, Planken M Van der, Stevens WJ et al. Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression. J Psychiatr Res 1992 c; 26: 125-134
13. Seidel A, Arolt V, Hunstiger M et al. Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand 1996 a; 94: 198-204
14. Castilla-Cortazar I, Castilla A, Gurpegi M. Opioid peptides and immunodysfunction in patients with major depression and anxiety disorders. J Physiol Biochem 1998; 54: 203-215
15. Irwin M, Smith TL, Gillin JC. Low natural killer cytotoxicity in major depression. Life Sci 1987; 41: 2127-2133
16. Darko DF, Gillin JC, Risch SC et al. Immune Cells and the Hypothalamic-Pituitary Axis in Major Depression. Psychiatry Res 1988; 25: 173-179
17. Maes M, Meltzer HY, Stevens W et al. Natural Killer Cell Activity In Major Depression: Relation To Circulating Natural Killer Cells, Cellular Indices Of The Immune Response, And Depressive Phenomenology. Progr Neuropsychopharmacol Biol Psychiatry 1994 c; 18: 717-730
18. Anesi A, Franciotta D, Paolo E Di et al. PHA-Stimulated Cellular Immune Function And T-Lymphocyte Subsets In Major Depressive Disorders. Funct Neurol 1994; 9: 17-22
19. McAdams C, Leonard BE. Neutrophil and monocyte phagocytosis in depressed patients. Progr Neuropsychopharmacol Biol Psychiatry 1993; 17: 971-984
20. Maes M, Bosmans E, Suy E et al. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991 a; 84: 379-386
21. Maes M, Bosmans E, Meltzer HY et al. Interleukin-1beta: A putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993 a; 150: 1189-1193
22. Weizman R, Laor N, Podliszewski E et al. Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry 1994; 35: 42-47
23. Maes M, Meltzer HY, Bosmans E et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Dis 1995 b; 34: 301-309
24. Maes M, Bosmans E, Jongh R de et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997 a; 9: 853-858
25. Haack M, Hinze-Selch D, Fenzel T et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33; 407-418
26. Maes M, Meltzer HY, Buckley P, Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 1995 c; 244: 325-329
27. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Progr Neuropsychopharmacol Biol Psychiatry 1995 d; 19: 11-38
28. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999; 4: 182-188
29. Darko DF, Gillin JC, Risch SC et al. Mitogen-stimulated lymphocyte proliferation and pituitary hormones in major depression. Biol Psychiatry 1989; 26: 145-155
30. Natelson BH, Denny T, Zhou XD et al. Is depression associated with immune activation? J Affect Disord 1999; 53: 179-184
31. Inglot AD, Leszek J, Piasecki E, Sypula A. Interferon responses in schizophrenia and major depressive disorders. Biol Psychiatry 1994; 35: 464-473
32. Maes M, Scharpe S, Meltzer HY et al. Increased neopterin and interferon-gamma secretion and lower avaibility of 1-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994 d; 54: 143-160
33. Seidel A, Arolt V, Hunstiger M et al. Increased CD56+Natural Killer Cells and Related Cytokines in Major Depression. Clin Immunol Immunopathol 1996 b; 78: 83-85
34. Rothermundt M, Arolt V, Fenker J et al. Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 2001 b; 251: 90-97
35. Rothermundt M, Arolt V, Peters M et al. Inflammatory markers in major depression and melancholia. J Affect Disord 2001 c; 63: 93-102
36. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002; 25: 154-159
37. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003; 25: 34-38
38. Capuron L, Ravaud A, Neveu PJ et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002 b; 7: 468-473
39. Widner B, Laich A, Sperner-Unterweger B et al. Neopterin production, tryptophan degradation, and mental depression - what is the link? Brain Behav Immun 2002; 16: 590-595
40. Reichenberg A, Yirmiya R, Schuld A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 45-452
41. Pollmächer T, Haack M, Schuld A et al. Low levels of circulating inflammatory cytokines - Do they affect human brain functions? Brain Behav Immun 2002; 16: 525-532
42. Merali Z, Brennan K, Brau P, Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1 beta: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacol 2003; 165: 413-418
43. Capuron L, Gumnick JF, Musselman DL et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol 2002 a; 26: 643-652
44. Wong CM. Post-traumatic stress disorder: advances in psychoneuroimmunology. Psychiatr Clin North Am 2002; 25: 369-383
45. Boscarino JA, Chang J. Higher abnormal leukocyte and lymphocyte counts 20 years after exposure to severe stress: research and clinical implications. Psychosom Med 1999; 61: 378-386
46. Weiss DW, Hirt R, Tarcic N et al. Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behavioral Med 1996; 22: 5-14
47. Wilson SN, Kolk B van der, Burbridge J et al. Phenotype of blood lymphocytes in PTSD suggests chronic immune activation. Psychosomatics 1999; 40: 222-225
48. Laudenslager ML, Aasal R, Adler L et al. Elevated cytotoxicity in combat veterans with long-term post-traumatic stress disorder: preliminary observations. Brain Behav Immun 1998; 12: 74-79
49. Watson IP, Muller HK, Jones ICH, Bradley AJ. Cell-mediated immunity in combat veterans with post-traumatic stress disorder. Med J Australia 1993; 159: 513-516
50. Gotovac K, Sabioncello A, Rabatic S et al. Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in patients with post-traumatic stress disorder (PTSD). Clin Exp Immunol 2003; 131: 335-339
51. Maes M, Lin AH, Delmeire L et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999 a; 45: 833-839
52. Lehmann-Facius H. Liquoruntersuchungen bei destruktiven Erkrankungen des Nervensystems, besonders bei Schizophrenien. Neurologie Psychiatrie 1937; 157: 109-115
53. Torrey EF, Miller J, Rawlings R, Yolken RH. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 1997; 28: 1-38
54. Wright P, Gill M, Murray RM. Schizophrenia: Genetics and the maternal immune response to viral infection. Am J Med Gen 1993; 48: 40-46
55. Kirch DG. Infection and autoimmunity as etiologic factors in schizophrenia: A review and reappraisal. Schizophr Bull 1993; 19: 355-370
56. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001 a; 15: 319-339
57. Ganguli R, Rabin BS. Increased serum interleukin-2 receptor in schizophrenic and brain damaged subjects. Arch Gen Psychiatry 1989; 46: 291-292
58. Rapaport MH, McAllister CG, Pickar D et al. Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch Gen Psychiatry 1989; 46: 291-292
59. Hornberg M, Arolt V, Wilke I et al. Lymphokine production in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995; 15: 237-242
60. McAllister CG, Kammen DP van, Rehn TJ et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995; 152: 1291-1297
61. Rapaport MH, Lohr JB. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 1994; 90: 311-315
62. Schwarz MJ, Ackenheil M, Riedel M, Müller N. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 1998; 253: 201-203
63. Müller N, Riedel M, Hadjamu M et al. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 1999 b; 156: 634-636
64. Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Progr Neuropsychopharmacol Biol Psychiatry 1998; 22: 1-33
65. Müller N, Riedel M, Ackenheil M, Schwarz MJ. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 1999 a; 249, Suppl 4: 62-68
66. Moises HW, Schindler L, Leroux M, Kirchner H. Decreased production of Interferon alpha and Interferon gamma in leukocyte cultures of schizophrenic patients. Acta Psychiatr Scand 1985; 72: 45-50
67. Villemain F, Chatenoud L, Guillibert E et al. Decreased production of interleukin-2 in schizophrenia. Ann N Y Acad Sci 1987; 469: 669-675
68. Villemain F, Chatenoud L, Galinowski A et al. Aberrant T-cell mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 1989; 146: 609-616
69. Ganguli R, Rabin BS, Belle SH. Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 1989; 26: 427-430
70. Licinio J, Seibyl JP, Altemus M et al. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993; 150: 1408-1410
71. El-Mallakh RS, Suddath RL, Wyatt RJ. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 383-391
72. Barak V, Barak Y, Levine J et al. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 1995; 6: 61-69
73. Rapaport MH, McAllister CG, Pickar D et al. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 1997; 25: 123-129
74. Wilke I, Arolt V, Hornberg M, Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenics. Eur Arch Psychiatry Clin Neurosci 1996; 246: 279-284
75. Rothermundt M, Arolt V, Weitzsch C et al. Decreased production of IFN-γ acute schizophrenia. Biol Psychiatry 1996; 40: 1294-1297
76. Rothermundt M, Arolt V, Weitzsch C et al. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiol 1998; 37: 186-193
77. Rothermundt M, Arolt V, Leadbeater J et al. Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 2000; 11: 3385-3388
78. Arolt V. Weitzsch C. Wilke I et al. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res 1997 a; 66: 145-151
79. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000; 5: 150-158
80. Sivieri S, Ferrarini AM, Gallo P. Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls. Mult Sclerosis 1998; 4: 7-11
81. Schwarz MJ, Chiang S, Müller N, Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 2001; 15: 340-370
82. Andreoli AV, Keller SE, Rabaeus M et al. Immunity, major depression, and panic disorder comorbidity. Biol Psychiatry 1992; 31: 896-908
83. Surman OS, Williams J, Sheehan DV et al. Immunological response to stress in agoraphobia and panic attacks. Biol Psychiatry 1986; 21: 768-774
84. Brambilla F, Bellodi L, Perna G et al. Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiol 1992; 26: 12-22
85. Koh KB, Lee BK. Reduced lymphocyte proliferation and interleukin-2 production in anxiety disorders. Psychosom Med 1998; 60: 479-483
86. Rapaport MH. Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers. Biol Psychiatry 1998; 43: 458-463
87. Rapaport MH, Stein MB. Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia. Anxiety 1994 a; 1: 50-53
88. Rapaport MH, Stein MB. Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder. Anxiety 1994 b; 1: 22-25
89. Weizman R, Laor N, Wiener Z et al. Cytokine production in panic disorder patients. Clin Neuropharmacol 1999; 22: 107-109
90. Barber Y, Toren P, Achiron A et al. T cell subsets in obsessive-compulsive disorder. Neuropsychobiol 1996; 34: 63-66
91. Ravindran AV, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls. J Affect Disord 1999; 52: 1-10
92. Maes M, Meltzer HY, Bosmans E. Psychoimmune investigation in obsessive-compulsive disorder: assays of plasma transferrin, IL-2 and IL-6 receptor, and IL-1 beta and IL-6 concentrations. Neuropsychobiol 1994 b; 30: 57-60
93. Monteleone P, Catapone F, Fabrazzo M et al. Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder. Neuropsychobiol 1998; 37: 182-185
94. Weizman R, Laor N, Barber Y et al. Cytokine production in obsessive-compulsive disorder. Biol Psychiatry 1996; 40: 908-912
95. Arolt V, Weitzsch C, Rothermundt M et al. Interferon-gamma in schizophrenia. Recent Adv Biol Psychiatry 1997 b; 18: 57-66
96. Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacol 1997; 37: 75-86
97. Nozaki H, Hozumi K, Nishimura T, Habu S. Regulation of NK activity by the administration of bromocriptine in haloperidol-treated mice. Brain Behav Immunity 1996; 10: 17-26
98. Maes M, Bosmans E, Calabrese J et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995 a; 29: 141-152
99. Müller N, Empl M, Riedel M et al. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1997; 247: 308-313
100. Pollmächer T, Hinze-Seich D, Fenzel T et al. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 1997 b; 154: 1763-1765
101. Ghosh N, Chattopadhyay U. Enhancement of immune response by phenothiazine administration in vivo. In vivo 1993; 7: 435-440
102. Tarazona R, Gonzales-Garcia A, Zamzami N et al. Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 1995; 154: 861-870
103. Bessler H, Levental Z, Karp L et al. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 1995; 38: 297-302
104. Ganguli R, Bra JS, Solomon W et al. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 1992; 44: 113-123
105. Rudolf S, Peters M, Rothermundt M et al. The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in-vitro. Neuropsychobiol 2002; 46: 180-181
106. Maes M, Bosmans E, Ranjan R et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 1996; 21: 39-50
107. Pollmächer T, Hinze-Seich D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-409
108. Pollmächer T, Fenzel T, Mullington J, Hinze-Seich D. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels. Pharmacopsychiatry 1997 a; 30: 118-121
109. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994 a; 89: 346-351
110. Maes M, Bosmans E, Kenis G et al. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997 b; 26: 221-225
111. Hinze-Selch D, Becker EW, Stein GM et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacol 1998; 19: 114-122
112. Monteleone P, Fabrazzo M, Tortolla A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 1997; 71: 11-17
113. Kubera M, Basta-Kaim A, Skowron-Cendrzak A et al. Effect of repeated amitriptyline administration to mice on the T lymphocyte proliferative activity and natural killer cell cytotoxicity. Pol J Pharmacol 1995; 47: 321-326
114. Kubera M, Symbirtsev A, Basta-Kaim A et al. Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol 1996; 48: 503-506
115. Sacerdote P, Bianchi M, Panerai AE. In vivo and in vitro clomipramine treatment decreases the migration of macrophages in the rat. Eur J Pharmacol 1997; 319: 287-290
116. Eisen JN, Irwin J, Quay J, Livnat S. The effect of antidepressants on immune function in mice. Biol Psychiatry 1989; 26: 805-817
117. Henderson DC, Edwards RG, Weston BJ, Dewdney JM. Immunological studies on paroxetine, a novel anti-depressant drug. Int J Immunopharmacol 1998; 10: 361-367
118. Xiao L, Eneroth P. Tricyclic antidepressants inhibit human natural killer cells. Toxicol Appl Pharmacol 1996; 137: 157-162
119. Xia Z, DePierre JW, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacol 1996; 34: 27-37
120. Miller AH, Asnis GM, Praag HM van, Norm AJ. Influence of desmethyl-imipramine on natural killer cell activity. Psychiatry Res 1986; 19: 9-15
121. Maes M, Song C, Lin AH et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacol 1999 b; 20: 370-379
122. Pariante CM, Miller AH. Natural killer cell activity in major depression: a prospective study of the in vivo effects of desmethylimipramine treatment. Eur Neuropsychopharmacol 1995; 5, Suppl: 83-88
123. Landmann R, Schaub B, Link S, Wacher HR. Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biol Psychiatry 1997; 41: 675-681
124. Thiele B, Brink I, Ploch M. Modulation of cytokine expression by hypericum extract. J Geriatr Psychiatry Neurol 1994; 7, Suppl 1: 60-62
125. Ravindran AV, Griffiths J, Merali Z, Anisman H. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment. Psychosom Med 1995; 57: 555-563
126. Sluzewska A, Rybakowski JK, Laciak M et al. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 1995; 762: 474-476
127. Andreoli AV, Keller SE, Rabaeus M C et al. Depression and Immunity: Age, Severity, and Clinical Course. Brain Behav Immun 1993; 7: 279-292
128. Bauer ME, Gauer GJ, Luz C et al. Evaluation of immune parameters in depressed Patients. Life Sci 1995; 57: 665-674
129. Caldwell CL, Irwin M, Lohr J. Reduced natural killer cell cytotoxicity in depression but not in schizophrenia. Biol Psychiatry 1991; 30: 1131-1138
130. Castle S, Wilkins S, Heck E et al. Depression in caregivers of demented patients is associated with altered immunity: impaired proliferative capacity, increased CD8+, and a decline in lymphocytes with surface signal transduction molecules (CD38+) and a cytotoxicity marker (CD56+CD8+). Clin Exp Immunol 1995; 101: 487-493
131. Evans DL, Folds JD, Petitto JM et al. Circulating Natural Killer Cell Phenotypes in Men and Women With Major Depression. Arch Gen Psychiatry 1992; 49: 388-395
132. Hickie I, Hickie C, Lloyd A et al. Impaired in vivo immune responses in patients with melancholia. Br J Psychiatry 1993; 162: 651-657
133. Irwin M, Patterson T, Smith TL et al. Reduction of immune function in life stress and depression. Biol Psychiatry 1990; 27: 22-30
134. Kanba S, Manki H, Shintani F et al. Aberrant interleukin-2 receptor-mediated blastoformation of peripheral blood lymphocytes in a severe major depressive episode. Psychol Med 1998; 28: 481-484
135. Kook AI, Mizruchin A, Odnopozov N et al. Depression and immunity: the biochemical interrelationship between the central nervous system and the immune system. Biol Psychiatry 1995; 37: 817-819
136. Levy EM, Borrelli DJ, Mirin SM et al. Biological Measures and Cellular Immunological Function in Depressed Psychiatric Inpatients. Psychiatry Res 1991; 36: 157-167
137. Maes M, Bosmans E, Suy E et al. A further exploration of the relationships between immune parameters and the HPA-axis activity in depressed patients. Psychol Med 1991 b; 21: 313-320
138. Maes M, Stevens W, Peeters D et al. A Study On The Blunted Natural Killer Cell Activity In Severely Depressed Patients. Life Sci 1992 b; 50: 505-513
139. Maes M, Scharpe S, Meltzer HY, Cosyns P. Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol Psychiatry 1993 b; 34: 690-701
140. Miller AH, Asnis CM, Lackner C et al. Depression, natural killer cell activity, and cortisol secretion. Biol Psychiatry 1991; 29: 878-886
141. Natelson BH, LaManca JJ, Denny TN et al. Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis. Am J Med 1998; 105: 43S-49S
142. Ravindran AV, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom Med 1998; 60: 283-289
143. Reynaert C, Janne P, Bosly A et al. From health locus of control to immune control: internal locus of control has a buffering effect on natural killer cell activity decrease in major depression. Acta Psychiatr Scand 1995; 92: 294-300
144. Schleifer SJ, Keller SE, Bartlett JA et al. Immunity in Young Adults With Major Depressive Disorder. Am J Psychiatry 1996; 153: 477-482
145. Spurrell MT, Creed FH. Lymphocyte response in depressed patients and subjects anticipating bereavement. Br J Psychiatry 1993; 162: 60-64
146. Wodarz N, Rupprecht R, Kornhuber J et al. Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression. J Affect Disord 1991; 22: 241-248